# PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

> **NCT04815408** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 40 (estimated)

## Conditions studied

- Ovarian Cancer
- Neoadjuvant Chemotherapy
- Anti-PD-1
- Neoadjuvant Immunotherapy

## Interventions

- **DRUG:** BGB-A317
- **DRUG:** albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5

## Key facts

- **NCT ID:** NCT04815408
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2023-04-01
- **Final completion:** 2025-04-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04815408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04815408, "PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04815408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*